New study reveals key differences in miRNA expression between long-COVID and recovered patients
Nikhil Prasad Fact checked by:Thailand Medical News Team Sep 03, 2024 2 months, 2 weeks, 4 days, 21 hours, 45 minutes ago
Medical News: A groundbreaking study from researchers at the SB RAS Institute of Chemical Biology and Fundamental Medicine and Novosibirsk State University in Russia sheds light on the molecular mechanisms that differentiate patients with long-COVID symptoms from those who have fully recovered from COVID-19. This
Medical News report delves into the findings of this study, which focused on specific miRNAs (microRNAs) that play crucial roles in the immune response and their regulation in post-COVID-19 patients.
New study reveals key differences in miRNA expression between long-COVID
and recovered patients
Understanding the Study
The researchers analyzed three distinct groups of individuals: those with long-COVID symptoms, patients who had recovered from COVID-19 without any lingering complaints, and healthy donors who never contracted the virus. The focus of the study was on the levels of ten specific miRNAs in the plasma of these individuals. The study found significant differences in the expression of miR-200c-3p, miR-766-3p, and miR-142-3p between the groups, highlighting their potential roles in the immune response and recovery process.
Key Findings: miRNA Expression and Long COVID
One of the major findings of the study was the significant reduction in the expression of miR-200c-3p, miR-766-3p, and miR-142-3p in patients with long-COVID symptoms compared to those who had fully recovered and healthy donors. miR-200c-3p, in particular, was found to be elevated during the acute phase of COVID-19, correlating with disease severity. Its reduction in recovered patients suggests a return to normal immune function after recovery.
miR-142-3p is known to be involved in regulating inflammatory processes. The study found that its expression remained low even after recovery, indicating that normalization of immune function might take longer in some individuals, which could be linked to the persistence of symptoms in long-COVID patients.
Additionally, miR-766-3p, which has been associated with acute respiratory distress syndrome, also showed reduced expression in long-COVID patients, further supporting the idea that these miRNAs play a role in the lingering symptoms experienced by some individuals after recovering from COVID-19.
The Role of Catalytic Antibodies
The study also examined the role of IgG antibodies in the hydrolysis of miRNAs, hypothesizing that these antibodies might contribute to the regulation of miRNA levels in the blood. Interestingly, the study found that antibodies from long-COVID patients exhibited lower activity in hydrolyzing certain miRNAs, such as Flu-miR-146b-5p, Flu-miR-148a-3p, and Flu-miR-766-3p, compared to those from recovered patients and healthy donors. This reduced activity could be linked to the persistence of certain miRNAs in the blood, potentially contributing to the prolonged symptoms observed in long-COVID patients.
Conversely, an increase in the hydrolyzing activity against Flu-miR-378a-3p was observed in long-COVID patients, su
ggesting a complex regulatory mechanism at play that involves both the immune response and antibody-mediated miRNA hydrolysis.
Implications for Long COVID and Future Research
The findings of this study provide valuable insights into the molecular mechanisms underlying long COVID, particularly in relation to miRNA regulation and immune response. The reduced expression of certain miRNAs and the altered activity of catalytic antibodies suggest that long COVID may be driven by an ongoing dysregulation of the immune system, even after the virus has been cleared from the body.
These results open up new avenues for research into potential biomarkers for long COVID, as well as therapeutic targets that could help alleviate the persistent symptoms experienced by many patients. Further studies are needed to fully understand the complex interactions between miRNAs, antibodies, and the immune response in the context of COVID-19 and its long-term effects.
Conclusion: Moving Forward in Long COVID Research
In conclusion, the study findings provide crucial evidence that miRNA expression and antibody activity play significant roles in the persistence of long-COVID symptoms. By identifying specific miRNAs and their regulatory mechanisms, this research paves the way for more targeted approaches to diagnosing and treating long COVID.
As research into long COVID continues to evolve, studies like this one are essential for developing a deeper understanding of the condition and finding effective ways to support those who continue to suffer from its effects long after the acute phase of the virus has passed.
The study findings were published in the peer-reviewed journal: Non-Coding RNA.
https://www.mdpi.com/2311-553X/10/5/48
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/persistent-endothelial-dysfunction-oxidative-stress-and-lipid-peroxidation-are-found-in-women-with-post-covid-19-health-issues
https://www.thailandmedical.news/news/long-covid-patients-face-hidden-lung-problems-leading-to-persistent-breathlessness
Share
Tweet
Share
